Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience

Breast Cancer Research

Table 1 Summary of patient data

Study Number	Breast Density	Size (cm)	Pathology	Exams	Treatment	Radiographic Response	Pathologic Response
1	SC	7 × 6.5	IDC, ER+/PR-/HER2neu+	7	AC²/paclitaxel trastuzumab	Yes (MRI)	pCR
2	HD	5 × 3	IDC, ER-/PR-/HER2neu-	7	paclitaxel tocosol	No substantial response (MRI)	pPR2
3	SC	4 × 4	IDC, ER-/PR-/HER2neu-	5	TAC³	Yes (MRI)	pCR
4	HD	5 × 5	IDC, ER+/PR+/HER2neu+	5	AC²/paclitaxel trastuzumab	Yes (MRI)	pCR
5	ED	8 × 7	IDC, ER+/PR+/HER2neu-	10	AC²/paclitaxel	No substantial response (MRI)	pPR4
6	HD	1 × 1	IDC, ER equivocal/PR-/HER2neu+	8	Taxol/FEC/Herceptin	Yes (MRI)	pCR
7	ED	10 × 9	IDC, ER-/PR-/HER2neu+	4	TAC³	Yes (MRI)	pPR1
8	HD	4 × 4	IDC, ER+/PR+/HER2neu+	5	TAC³	No substantial response (MRI)	pPR3

AC², doxorubicin and cyclophosphamide; ED, extremely dense; ER, estrogen receptor; HD, heterogeneously dense; HER2-neu, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; pPR1, near total treatment effect (< 10% of tumor remaining) [32]; pPR2, evidence of response to therapy but with 10% to 50% of tumor remaining [32]; pPR3, evidence of response to therapy but with > 50% < 90% of tumor remaining [32]; pPR4, minimal evidence of response to therapy with > 90% of tumor remaining [32]; PR, progesterone receptor; SC, scattered; TAC³, docetaxel, doxorubicin, and cyclophosphamide.

ISSN: 1465-542X